| Michael Wonsung Taylor-cho, MD, MPH | |
|
1301 Punchbowl St, Honolulu, HI 96813-2499 | |
| (808) 691-1000 | |
| Not Available |
| Full Name | Michael Wonsung Taylor-cho |
|---|---|
| Gender | Male |
| Speciality | Diagnostic Radiology |
| Experience | 12 Years |
| Location | 1301 Punchbowl St, Honolulu, Hawaii |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1992062319 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0202X | Radiology - Diagnostic Radiology | 2015-02480 (North Carolina) | Secondary |
| 2085R0202X | Radiology - Diagnostic Radiology | MD-23713 (Hawaii) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| The Queens Medical Center | Honolulu, HI | Hospital |
| Duke University Hospital | Durham, NC | Hospital |
| North Hawaii Community Hospital | Kamuela, HI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Queen's North Hawaii Community Hospital | 0143116293 | 58 |
| Queens University Medical Group | 2466831557 | 543 |
News Archive
A new compound appears to prevent the traffic jam of cells that causes debilitating pain crises and associated mortality in sickle cell disease, Georgia Health Sciences University researchers report.
Blueprint Medicines today announced that the U.S. Food and Drug Administration accepted the Company's Investigational New Drug (IND) applications to begin Phase 1 clinical trials for its two lead drug candidates: BLU-554 for the treatment of advanced hepatocellular carcinoma (HCC) and cholangiocarcinoma, and BLU-285 for unresectable, treatment-resistant gastrointestinal stromal tumor (GIST).
The targeted cancer drug erlotinib has comparable efficacy to chemotherapy, and is better tolerated, in hard-to-treat cases where a patient's cancer has progressed quickly after treatment with first-line therapy, the results of a new phase III trial show.
Stopping bleeding, closing wounds, repairing organs—these are everyday challenges in medical and surgical practice. In the journal Angewandte Chemie, French researchers have now introduced a new method that employs gluing by aqueous nanoparticle solutions to effectively control bleeding and repair tissues. In animal tests, their approach proved easy to apply, rapid and efficient even in situations when conventional methods are traumatic or fail.
› Verified 1 days ago
| Entity Name | Queen's North Hawaii Community Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1528049814 PECOS PAC ID: 0143116293 Enrollment ID: O20040225000562 |
News Archive
A new compound appears to prevent the traffic jam of cells that causes debilitating pain crises and associated mortality in sickle cell disease, Georgia Health Sciences University researchers report.
Blueprint Medicines today announced that the U.S. Food and Drug Administration accepted the Company's Investigational New Drug (IND) applications to begin Phase 1 clinical trials for its two lead drug candidates: BLU-554 for the treatment of advanced hepatocellular carcinoma (HCC) and cholangiocarcinoma, and BLU-285 for unresectable, treatment-resistant gastrointestinal stromal tumor (GIST).
The targeted cancer drug erlotinib has comparable efficacy to chemotherapy, and is better tolerated, in hard-to-treat cases where a patient's cancer has progressed quickly after treatment with first-line therapy, the results of a new phase III trial show.
Stopping bleeding, closing wounds, repairing organs—these are everyday challenges in medical and surgical practice. In the journal Angewandte Chemie, French researchers have now introduced a new method that employs gluing by aqueous nanoparticle solutions to effectively control bleeding and repair tissues. In animal tests, their approach proved easy to apply, rapid and efficient even in situations when conventional methods are traumatic or fail.
› Verified 1 days ago
| Entity Name | Queens University Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1891441382 PECOS PAC ID: 2466831557 Enrollment ID: O20220621000534 |
News Archive
A new compound appears to prevent the traffic jam of cells that causes debilitating pain crises and associated mortality in sickle cell disease, Georgia Health Sciences University researchers report.
Blueprint Medicines today announced that the U.S. Food and Drug Administration accepted the Company's Investigational New Drug (IND) applications to begin Phase 1 clinical trials for its two lead drug candidates: BLU-554 for the treatment of advanced hepatocellular carcinoma (HCC) and cholangiocarcinoma, and BLU-285 for unresectable, treatment-resistant gastrointestinal stromal tumor (GIST).
The targeted cancer drug erlotinib has comparable efficacy to chemotherapy, and is better tolerated, in hard-to-treat cases where a patient's cancer has progressed quickly after treatment with first-line therapy, the results of a new phase III trial show.
Stopping bleeding, closing wounds, repairing organs—these are everyday challenges in medical and surgical practice. In the journal Angewandte Chemie, French researchers have now introduced a new method that employs gluing by aqueous nanoparticle solutions to effectively control bleeding and repair tissues. In animal tests, their approach proved easy to apply, rapid and efficient even in situations when conventional methods are traumatic or fail.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Michael Wonsung Taylor-cho, MD, MPH 1301 Punchbowl St, Honolulu, HI 96813-2499 Ph: (808) 691-1000 | Michael Wonsung Taylor-cho, MD, MPH 1301 Punchbowl St, Honolulu, HI 96813-2499 Ph: (808) 691-1000 |
News Archive
A new compound appears to prevent the traffic jam of cells that causes debilitating pain crises and associated mortality in sickle cell disease, Georgia Health Sciences University researchers report.
Blueprint Medicines today announced that the U.S. Food and Drug Administration accepted the Company's Investigational New Drug (IND) applications to begin Phase 1 clinical trials for its two lead drug candidates: BLU-554 for the treatment of advanced hepatocellular carcinoma (HCC) and cholangiocarcinoma, and BLU-285 for unresectable, treatment-resistant gastrointestinal stromal tumor (GIST).
The targeted cancer drug erlotinib has comparable efficacy to chemotherapy, and is better tolerated, in hard-to-treat cases where a patient's cancer has progressed quickly after treatment with first-line therapy, the results of a new phase III trial show.
Stopping bleeding, closing wounds, repairing organs—these are everyday challenges in medical and surgical practice. In the journal Angewandte Chemie, French researchers have now introduced a new method that employs gluing by aqueous nanoparticle solutions to effectively control bleeding and repair tissues. In animal tests, their approach proved easy to apply, rapid and efficient even in situations when conventional methods are traumatic or fail.
› Verified 1 days ago
Dr. Samuel M. Wu, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 3288 Moanalua Rd, Honolulu, HI 96819 Phone: 808-432-0000 | |
Dr. Horia Vulpe, MD, CM Radiology Medicare: Accepting Medicare Assignments Practice Location: 1301 Punchbowl St, Honolulu, HI 96813 Phone: 808-691-8777 Fax: 808-691-8780 | |
Howard K. Arimoto, M.D. Radiology Medicare: Not Enrolled in Medicare Practice Location: 347 N Kuakini St, Honolulu, HI 96817 Phone: 808-522-0190 Fax: 808-523-9068 | |
Dr. Mark T. Kanemori, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 1650 Liliha St, Suite 105, Honolulu, HI 96817 Phone: 808-524-3131 Fax: 808-524-3189 | |
Dr. Ferdinand K Hui, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 550 S Beretania St Ste 405, Honolulu, HI 96813 Phone: 808-691-8866 | |
Dr. Jean Paul Colon-pons, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 1380 Lusitana St Ste 1007, Honolulu, HI 96813 Phone: 808-748-4488 Fax: 808-748-4799 | |
Kristen T. Nagata, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 3288 Moanalua Rd, Honolulu, HI 96819 Phone: 808-432-0000 |